Radiation Oncology/RTOG Trials/9910

RTOG 99-10 (PROSTATE)
 * Title: A Phase III Trial to Evaluate The Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate Risk Prostate Cancer
 * Objective: To compare the efficacy of moderate-duration (28-week) neoadjuvant total androgen suppression and RT with short-duration (8-week) neoadjuvant total androgen suppression and RT as related to disease-specific survival.
 * Protocol:
 * Arm 1: TAS x 8 weeks followed by 70.2 Gy RT + concurrent TAS
 * Arm 2: TAS x 28 weeks followed by 70.2 Gy RT + concurrent TAS
 * Eligibility:
 * (cT1b-T4 and GS 2-6 and PSA 10-100) or
 * (cT1b-T4 and GS 7 and PSA <20) or
 * (T1b-T1c and GS 8-10 and PSA <20)
 * N0M0
 * Enrollment Target: 1540 patients
 * Activation: February 14, 2000
 * Closed: May 3, 2004